Century Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule

Reuters

Aug 30

Century <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule

Century Therapeutics Inc. announced it received a deficiency letter from Nasdaq on February 26, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Despite efforts, the company failed to meet this requirement by the initial compliance deadline of August 26, 2025. Subsequently, Nasdaq approved Century Therapeutics' transfer to The Nasdaq Capital Market on August 27, 2025, and granted an additional 180-day period until February 23, 2026, to regain compliance. The company is considering options, including a reverse stock split, to address the deficiency, though there is no assurance of compliance with this or other Nasdaq listing criteria.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-085658), on August 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2563717140"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563717140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563717140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-30 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563717140","market":"fut","top_or_hot":-1,"title":"Century Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Century Therapeutics Inc. announced it received a deficiency letter from Nasdaq on February 26, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Despite efforts, the company failed to meet this requirement by the initial compliance deadline of August 26, 2025. Subsequently, Nasdaq approved Century Therapeutics' transfer to The Nasdaq Capital Market on August 27, 2025, and granted an additional 180-day period until February 23, 2026, to regain compliance. The company is considering options, including a reverse stock split, to address the deficiency, though there is no assurance of compliance with this or other Nasdaq listing criteria.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-085658), on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Century Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentury Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-30 04:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Century Therapeutics Inc. announced it received a deficiency letter from Nasdaq on February 26, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Despite efforts, the company failed to meet this requirement by the initial compliance deadline of August 26, 2025. Subsequently, Nasdaq approved Century Therapeutics' transfer to The Nasdaq Capital Market on August 27, 2025, and granted an additional 180-day period until February 23, 2026, to regain compliance. The company is considering options, including a reverse stock split, to address the deficiency, though there is no assurance of compliance with this or other Nasdaq listing criteria.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-085658), on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL2nbT62:1","article_id":"2563717140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563717140","pubTimestamp":1756498283,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Century Therapeutics Inc. announced it received a deficiency letter from Nasdaq on February 26, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Despite efforts, the company failed to meet this requirement by the initial compliance deadline of August 26, 2025. Subsequently, Nasdaq approved Century Therapeutics' transfer to The Nasdaq Capital Market on August 27, 2025, and granted an additional 180-day period until February 23, 2026, to regain compliance. The company is considering options, including a reverse stock split, to address the deficiency, though there is no assurance of compliance with this or other Nasdaq listing criteria.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","BK4505":"高瓴资本持仓","IPSC":"Century Therapeutics, Inc."},"translate_title":"Century Therapeutics Inc.因不遵守最低投标价格规则而面临纳斯达克上市挑战","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPSC":0.9},"content_text":"Century Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule\n    \n\n        Century Therapeutics Inc. announced it received a deficiency letter from Nasdaq on February 26, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Despite efforts, the company failed to meet this requirement by the initial compliance deadline of August 26, 2025. Subsequently, Nasdaq approved Century Therapeutics' transfer to The Nasdaq Capital Market on August 27, 2025, and granted an additional 180-day period until February 23, 2026, to regain compliance. The company is considering options, including a reverse stock split, to address the deficiency, though there is no assurance of compliance with this or other Nasdaq listing criteria.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-085658), on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}